Skip to main content

COVID-19 UPDATES >VISIT JANSSEN GLOBAL

Xian Janssen Pharmaceutical Ltd.

中国

?
  • 简体中文
  • English
?
SEARCH

?

?
?
?
?
?
?
  • 简体中文
  • English

Collaborating in more than 150 countries.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com. These sections or websites are governed by their own Legal and Privacy Policies.

关闭
Global
  • Janssen Global

    English|Espa?ol
    Fran?ais|Português(BR)
    Italiano|???
    РУССКИЙ

Asia Pacific
  • Asia Pacific (Regional)

    English

  • Australia

    English

  • China

    中文

  • India

    English

  • Japan

    日本

  • Korea

    ???

  • New Zealand

    English

Europe, Middle East & Africa (EMEA)
  • EMEA (Regional)

    English

  • Austria

    Deutsch

  • Belgium

    English | Fran?ais | Nederlands

  • Croatia

    HRVATSKI

  • Czech Republic

    ?e?tina

  • Denmark

    Dansk

  • Estonia

    English

  • Finland

    Suomi

  • France

    Fran?ais

  • Germany

    Deutsch

  • Greece

    ΕΛΛΗΝΙΚΑ

  • Hungary

    Magyar

  • Ireland

    English

  • Israel

    ?????

  • Italy

    Italiano

  • Kazakhstan

    Русский

  • Latvia

    English

  • Lithuania

    English

  • Netherlands

    Nederlands

  • Norway

    Norsk

  • Poland

    Polski

  • Portugal

    Português

  • Romania

    Rom?n?

  • Russia

    Русский

  • Slovakia

    SLOVEN?INA

  • Slovenia

    Sloven??ina

  • South Africa

    English

  • Spain

    Espa?ol

  • Sweden

    Svensk

  • Switzerland

    Deutsch | Fran?ais

  • Turkey

    Türk?e

  • United Kingdom

    English

Latin America
  • Argentina

    Espa?ol

  • Bolivia

    Espa?ol

  • Brazil

    Português

  • Central America and the Caribbean

    Spanish | English

  • Chile

    Espa?ol

  • Colombia

    Espa?ol

  • Mexico

    Espa?ol

  • Paraguay

    Espa?ol

  • Peru

    Espa?ol

  • Uruguay

    Espa?ol

North America
  • Canada

    English | Fran?ais

  • United States

    English

Welcome to Xian Janssen

About Xian JanssenPrescription Products OTC Products THERAPEUTIC AREA Contact Us
  • Home
  • >
  • News Center
  • >
  • Company Announcement

Company Announcement

2019/05/16
Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review
Highlights progress and commitment to deliver breakthrough medicines to meet the needs of patients around the world Plans to maximize potential of lea...
2017/09/08
[Media Report] Serving In the Name of Progress
In an interview with China Daily, Joaquin Duato, Executive Vice-President and Worldwide Chairman of Pharmaceuticals at Johnson&Johnson
2017/08/30
China Food and Drug Administration approves IMBRUVICA? (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs
[Beijing], [30 August, 2017] – Xian Janssen Pharmaceutical Ltd.
2017/08/05
Enlightened Light, Blooming Bright -- 14th Johnson & Johnson China World Window on Pediatrics Seminar Draws to a Successful Conclusion
The 14th?Johnson & Johnson China World Window on Pediatrics Seminar, co-hosted by Shanghai Johnson & Johnson Pharmaceuticals Ltd. and Xian Jan...
2016/01/08
ZYTIGA? - New prostate cancer treatment now available to patients across China
January 8, 2016, Beijing – Today, Xian Janssen Pharmaceutical Ltd., announced the launch of ZYTIGA? (abiraterone acetate), a new kind of treatment for...
2015/10/13
Xian Janssen Celebrates 30 Years of Commitment to China
Xi’an, China, 13 October 2015 – Xian-Janssen reaffirmed its commitment to partner with the Chinese Government and invest in healthcare innovation in C...
Contact Us

Beijing Headquarters

  • Address: 14F, Tower 3, China Central Place, No.77, Jian...
I want to
No thanks
  • 代表-1

XML 地图 | Sitemap 地图